Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
September 29, 2011

Medtronic commences Engager system trial

Medtronic has initiated the pivotal trial to obtain CE mark approval for its Engager transcatheter aortic valve implantation system, used to treat patients suffering from severe aortic stenosis.

Medtronic has initiated the pivotal trial to obtain CE mark approval for its Engager transcatheter aortic valve implantation system, used to treat patients suffering from severe aortic stenosis.

The Engager transapical valve incorporates bovine tissue leaflets and a self-expanding nitinol frame, designed to facilitate accurate positioning and stability when implanted.

The 150-patient trial conducted at 11 centres will evaluate the safety and clinical performance of the new valve and delivery system.

The Engager therapy will provide physicians with a transapical valve therapy option for patients with severe aortic stenosis, while facilitating minimally invasive delivery via a catheter inserted in the apex of the heart.

Medtronic Structural Heart Business president John Liddicoat said that transapical valve delivery can be a valuable alternative for cardiac surgeons, who will want to consider various approaches for patients who are at high risk for open-heart surgery or patients suffering from peripheral artery disease.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management